Search research articles
Contact Us
Filters
Showing results (111-120 of 131) with videos related to
Page
of 14
Sort By:
Cancer Discovery
|
June 14, 2025
Phase Ib basket expansion trial and alternative-schedule dose-escalation study of ATR inhibitor elimusertib in advanced solid tumors with DNA damage response defects
Timothy A Yap, David S P Tan, Anastasios Stathis, et al.
Blood Advances
|
January 30, 2025
Six-month rituximab-lenalidomide regimen in advanced untreated follicular lymphoma: SAKK 35/10 trial 10-year update
Eva Kimby, Sämi Schär, Maria Cristina Pirosa, et al.
The Oncologist
|
August 14, 2015
Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue of the Salivary Glands: A Multicenter, International Experience of 248 Patients (IELSG 41)
Amie E Jackson, Michael Mian, Christina Kalpadakis, et al.
Cell Reports
|
June 15, 2025
An integrated proteomic portrait of prostate cancer progression
Jichang Zhang, Keith D Rivera, Daniela Bossi, et al.
Haematologica
|
April 29, 2022
Resistance to PI3Kδ inhibitors in marginal zone lymphoma can be reverted by targeting the IL-6/PDGFRA axis
Alberto J Arribas, Sara Napoli, Luciano Cascione, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 13, 2022
Report of the First International Symposium on NUT Carcinoma
Christopher A French, Michael L Cheng, Glenn J Hanna, et al.
Haematologica
|
November 2, 2020
Targeting CD205 with the antibody drug conjugate MEN1309/OBT076 is an active new therapeutic strategy in lymphoma models
Eugenio Gaudio, Chiara Tarantelli, Filippo Spriano, et al.
Cancer Research Communications
|
September 15, 2023
A Phase I Study of the Pan-Notch Inhibitor CB-103 for Patients with Advanced Adenoid Cystic Carcinoma and Other Tumors
Glenn J Hanna, Anastasios Stathis, Elena Lopez-Miranda, et al.
Blood Advances
|
January 5, 2024
IELSG30 phase 2 trial: intravenous and intrathecal CNS prophylaxis in primary testicular diffuse large B-cell lymphoma
Annarita Conconi, Annalisa Chiappella, Andrés J M Ferreri, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 26, 2017
PQR309 Is a Novel Dual PI3K/mTOR Inhibitor with Preclinical Antitumor Activity in Lymphomas as a Single Agent and in Combination Therapy
Chiara Tarantelli, Eugenio Gaudio, Alberto J Arribas, et al.
Page
of 14
Search research articles
Search
Showing results (111-120 of 131) with videos related to
Sort By:
Page
of 14
Cancer Discovery
|
June 14, 2025
Phase Ib basket expansion trial and alternative-schedule dose-escalation study of ATR inhibitor elimusertib in advanced solid tumors with DNA damage response defects
Timothy A Yap, David S P Tan, Anastasios Stathis, et al.
Blood Advances
|
January 30, 2025
Six-month rituximab-lenalidomide regimen in advanced untreated follicular lymphoma: SAKK 35/10 trial 10-year update
Eva Kimby, Sämi Schär, Maria Cristina Pirosa, et al.
The Oncologist
|
August 14, 2015
Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue of the Salivary Glands: A Multicenter, International Experience of 248 Patients (IELSG 41)
Amie E Jackson, Michael Mian, Christina Kalpadakis, et al.
Cell Reports
|
June 15, 2025
An integrated proteomic portrait of prostate cancer progression
Jichang Zhang, Keith D Rivera, Daniela Bossi, et al.
Haematologica
|
April 29, 2022
Resistance to PI3Kδ inhibitors in marginal zone lymphoma can be reverted by targeting the IL-6/PDGFRA axis
Alberto J Arribas, Sara Napoli, Luciano Cascione, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 13, 2022
Report of the First International Symposium on NUT Carcinoma
Christopher A French, Michael L Cheng, Glenn J Hanna, et al.
Haematologica
|
November 2, 2020
Targeting CD205 with the antibody drug conjugate MEN1309/OBT076 is an active new therapeutic strategy in lymphoma models
Eugenio Gaudio, Chiara Tarantelli, Filippo Spriano, et al.
Cancer Research Communications
|
September 15, 2023
A Phase I Study of the Pan-Notch Inhibitor CB-103 for Patients with Advanced Adenoid Cystic Carcinoma and Other Tumors
Glenn J Hanna, Anastasios Stathis, Elena Lopez-Miranda, et al.
Blood Advances
|
January 5, 2024
IELSG30 phase 2 trial: intravenous and intrathecal CNS prophylaxis in primary testicular diffuse large B-cell lymphoma
Annarita Conconi, Annalisa Chiappella, Andrés J M Ferreri, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 26, 2017
PQR309 Is a Novel Dual PI3K/mTOR Inhibitor with Preclinical Antitumor Activity in Lymphomas as a Single Agent and in Combination Therapy
Chiara Tarantelli, Eugenio Gaudio, Alberto J Arribas, et al.
Page
of 14